Chat with us, powered by LiveChat
KoreaTech Today - Korea's Leading Tech and Startup Media Platform
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
No Result
View All Result
KoreaTech Today - Korea's Leading Tech and Startup Media Platform
No Result
View All Result
Home Celltrion

Celltrion to Establish China’s Biggest Biologics Plant

 252 total views,  1 views today

KoreaTechToday Editor by KoreaTechToday Editor
PUBLISHED: January 21, 2020 UPDATED: January 22, 2020
in Celltrion, China, Healthcare
0
celltrion

Hubei provincial government official Ma GuoQiang (right) discussing business with Celltrion’s Vice Chairman Kee Woo-sung (left) in Wuhan, China. / photo courtesy by Celltrion

Celltrion announced on Tuesday that the company would establish its first plant in Wuhan, China, stating that the facility would be China’s biggest biologics plant. The company hopes to develop and manufacture biologic drugs for the Chinese market at this Wuhan plant.

Celltrion is a biopharmaceutical company that develops, markets, and distributes biological medicines. The company, headquartered in Incheon, South Korea, aims to contribute to the improvement of patient welfare and access to healthcare by providing innovative biologics to the world.

Wuhan possesses a geographical advantage in shipping its products to the whole country. The city also houses over 300 significant research and development facilities making it a fast-growing bioindustry cluster.

The Hubei provincial government gave full support to the Celltrion Group in building a facility that would be able to manufacture 120,000 liters of biologic drugs. Currently, China’s largest facility can only produce 5,000 liters.

The Celltrion Group, through its existing cash reserves and outside investors, assigned a budget of more than 600 billion won ($514 million) until 2025.

Also, underway is the development of a direct logistics network for the company’s biosimilar products targeting China, being the world’s second-largest healthcare market.

Celltrion hopes to sign contracts for manufacturing organization deals with local biotechs.

Since 2017, China’s National Reimbursement List added several biologic drugs with local healthcare policy watchers, saying that the addition may be a forerunner to an increase in biologic drug demand in the country.

The biopharmaceutical company stated it is observing the changing trends in China’s policies, wanting to continuously export its existing biosimilars such as Remsima, Herzuma, and Truxima, in addition to other future biosimilars.

Celltrion recently developed a new type of biosimilar named Humira. The company also intends to target the diabetes treatment market with an insulin biosimilar.

The Wuhan plant would be Celltrion’s first business venture in China, holding a groundbreaking ceremony for the facility in April this year.

What’s your thoughts?
+1
0
Upvote
+1
0
Clap
+1
0
Clap
+1
0
On fire
+1
0
Meh
+1
0
Clap
+1
0
Tags: biologics plantCelltrionchinadrugWuhan

Related Posts

The Com2us mobile game, "Summoners War: Sky Arena," received approval from China 's National Press and Publication Administration. /photo taken from Com2us website
China

China Grants Approval of Com2us Korean Game for First Time in 4 Years

December 8, 2020
Naver D2SF invests in logistics solutions provider Techtaka and digital healthcare solutions provider Medibloc.
Healthcare

Naver D2SF Invests in Logistics Techtaka, Digital Healthcare Medibloc

December 3, 2020
Startup Looxid Labs Inc. announced that it would unveil its cognitive care solution "LUCY" at the Facebook Accelerator Seoul Demo Day on December 2, 2020. / photo courtesy of Looxid Labs
Healthcare

Looxid Labs to Unveil Senior Cognitive Care Solution LUCY at Facebook Accelerator Seoul Demo Day

December 1, 2020
President Moon Jae-in giving a speech about the country's biotechnology industry during a signing ceremony held at Yonsei University Global Campus in Songdo, Incheon.
Biotech

South Korean Firms to Inject 10 Trillion Won into Biotechnology by 2023

November 19, 2020
Samsung Biologics delivers first batch of Eli Lilly's COVID-19 antibody treatment.
Coronavirus

Samsung Biologics to Manufacture Eli Lilly‘s COVID-19 Antibody Treatment

November 19, 2020
SK Telecom's AI-based dementia detection system
AI

SK Telecom Conducts Trials for AI-Based Dementia Detection Tech

November 3, 2020

FREE NEWSLETTER

  • NAVER

  • Kakao

  • Nexon

  • Netmarble

  • Ncsoft

  • Samsung

  • Hyundai

  • SK

  • LG

  • KT

Trending posts

  • LG Chem Officially Launches LG Energy Solution Spinoff

     610 total views,  4 views today

  • LG Develops Autonomous Robot With UV Light for Disinfection

     463 total views,  3 views today

  • LG Uplus Exhibits 5G-Powered Autonomous Parking Technology in Seoul

     443 total views,  4 views today

  • LG to Start Electric Car Gear Joint Venture with Canada’s Magna

     339 total views,  3 views today

  • Samsung, LG Products Amass Innovation Awards for CES 2021

     503 total views,  5 views today

  • Hyundai Motor Introduces New E-GMP Platform for Battery Electric Vehicle

     432 total views,  5 views today

  • South Korea to Introduce a New Public Key Certification System

     390 total views,  5 views today

  • LG Energy Solutions Signs Lithium Supply Deal with Chile’s SQM

     349 total views,  4 views today

  • Motional, Lyft to Launch Driverless Robotaxi Service in U.S. by 2023

     343 total views,  3 views today

  • SK Telecom Collaborates With AWS to Launch 5G Edge Cloud Service

     363 total views,  9 views today

More from our network


  • ktd

  • atd

  • itd

  • ktt

  • kgd

  • kpp

  • ktp

  • kpoppost

  • ustechtimes
  • About Us
  • Account Page
  • application form
  • Cookie policy
  • Default Redirect Page
  • homepage
  • Login
  • login form
  • LogOut
  • Privacy Policy
  • Register
  • Reset Password
  • Sample Page
  • Subscription Plan
  • Terms of Use
  • test
  • test
  • testpage
  • TOS Page
  • Visitor Inside User Page

Copyright © 2020 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy|Contact : press@koreatechtoday.com |

No Result
View All Result
  • About Us
  • Account Page
  • application form
  • Cookie policy
  • Default Redirect Page
  • homepage
  • Login
  • login form
  • LogOut
  • Privacy Policy
  • Register
  • Reset Password
  • Sample Page
  • Subscription Plan
  • Terms of Use
  • test
  • test
  • testpage
  • TOS Page
  • Visitor Inside User Page

Copyright © 2020 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy|Contact : press@koreatechtoday.com |

Get the latest from the biggest tech companies in Korea straight to your email. Subscribe now!